European stocks jump 1.82% as Novo Nordisk surges
Bank and clean-energy shares rose, while technology stocks fell. Novo Nordisk raised its 2026 outlook again after Wegovy pill performance exceeded expectations.
Related stories
Upstart Raises Fee Outlook but Cuts 2026 Revenue and EBITDA Forecasts
Upstart reported Q3 2026 revenue of $370.5 million, up 34% year over year, and earnings of 66 cents per share. It lowered 2026 revenue guidance to approximately $1.35 billion from
M impact | EQUITY | Nov 04, 2026, 07:04 PM UTC
NNN REIT Reports Higher Q3 Earnings, Revenue and FFO
Third-quarter 2026 net earnings were $0.57 per diluted share versus $0.51 a year earlier. Core FFO and AFFO per diluted share increased 5.9% and 5.8% to $0.90 and $0.91, respective
M impact | EQUITY | Nov 04, 2026, 07:03 PM UTC
Skyworks Forecasts Q1 Revenue of $1.8B-$1.9B, Below Estimates
Skyworks also guided for adjusted earnings of $1.25 per share, below the $1.57 consensus estimate. It expects Android business to decline by more than 20% in the December quarter,
M impact | EQUITY | Nov 04, 2026, 07:03 PM UTC
Coupang Revenue Rises 7% to $9.96 Billion in Q3
Coupang reported a $0.28 per-share loss, including about $248 million in costs tied to a July fire at a leased Incheon fulfillment center; excluding the fire impact, the loss was $
M impact | EQUITY | Nov 04, 2026, 07:03 PM UTC
Sanofi Ends Autoimmune Disease Drug Program
Nurix says Sanofi is ending its program related to drugs for autoimmune diseases.
L impact | EQUITY | Nov 04, 2026, 07:01 PM UTC
Expeditors Reports Third-Quarter Revenue of $4.11 Billion, EPS of $2.65
Revenue rose 41.9% year over year to $4.11 billion, net income attributable to shareholders increased 55% to $344.5 million, and diluted EPS climbed 61.6% to $2.65.
M impact | EQUITY | Nov 04, 2026, 07:01 PM UTC